FY2024 EPS Estimates for OptiNose Boosted by HC Wainwright

OptiNose, Inc. (NASDAQ:OPTN) – Equities researchers at HC Wainwright upped their FY2024 EPS estimates for OptiNose in a report issued on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.18) for the year, up from their prior estimate of ($0.22). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OptiNose’s FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.35 EPS.

Separately, Piper Sandler reduced their target price on OptiNose from $3.00 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday.

OptiNose Price Performance

Shares of OptiNose stock opened at $0.46 on Friday. OptiNose has a fifty-two week low of $0.44 and a fifty-two week high of $2.10. The business’s fifty day moving average is $0.76 and its two-hundred day moving average is $0.96.

Hedge Funds Weigh In On OptiNose

Large investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC increased its holdings in shares of OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock worth $3,811,000 after buying an additional 3,338,580 shares during the last quarter. FMR LLC raised its holdings in shares of OptiNose by 3.2% in the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock worth $11,083,000 after purchasing an additional 518,610 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of OptiNose by 5.3% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock worth $2,061,000 after purchasing an additional 155,329 shares during the period. GSA Capital Partners LLP acquired a new position in shares of OptiNose in the 3rd quarter valued at about $61,000. Finally, Easterly Investment Partners LLC grew its holdings in shares of OptiNose by 5.0% during the 3rd quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock worth $1,581,000 after purchasing an additional 113,015 shares during the period. Hedge funds and other institutional investors own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.